Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 3:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 3,085 matching trials from the live ClinicalTrials.gov search.
Conditions
Patient Readmission, Arthroplasty, Replacement, Knee, Arthroplasty, Replacement, Hip, Heart Failure, Pulmonary Disease, Chronic Obstructive, Renal Insufficiency, Body Mass Index, Alcoholism
Interventions
Nurse Navigator Program
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Vascular Injury
Interventions
Vascular Injury
Procedure
Lead sponsor
Methodist Health System
Other
Eligibility
16 Years and older
Enrollment
5,718 participants
Timeline
2021 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Hepatobiliary Neoplasm, Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Genitourinary System Neoplasm, Malignant Neoplasm, Pathologic Stage 0 Esophageal Adenocarcinoma AJCC v8, Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage 0 Gastric Cancer AJCC v8, Pathologic Stage I Esophageal Adenocarcinoma AJCC v8, Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage I Gastric Cancer AJCC v8, Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IA Gastric Cancer AJCC v8, Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IB Gastric Cancer AJCC v8, Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage II Gastric Cancer AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIA Gastric Cancer AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Stage 0 Colorectal Cancer AJCC v8, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage I Cervical Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage I Ovarian Cancer AJCC v8, Stage I Prostate Cancer AJCC v8, Stage I Renal Cell Cancer AJCC v8, Stage I Uterine Corpus Cancer AJCC v8, Stage IA Cervical Cancer AJCC v8, Stage IA Ovarian Cancer AJCC v8, Stage IA Uterine Corpus Cancer AJCC v8, Stage IA1 Cervical Cancer AJCC v8, Stage IA2 Cervical Cancer AJCC v8, Stage IB Cervical Cancer AJCC v8, Stage IB Ovarian Cancer AJCC v8, Stage IB Uterine Corpus Cancer AJCC v8, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer AJCC v8, Stage IC Ovarian Cancer AJCC v8, Stage II Bladder Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage II Renal Cell Cancer AJCC v8, Stage II Uterine Corpus Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIA Ovarian Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIB Ovarian Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Patient Monitoring, Questionnaire Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Duarte, California
Conditions
Cervical Carcinoma, Dyspareunia, Endometrial Carcinoma, Ovarian Carcinoma, Vaginal Carcinoma, Vaginal Dryness, Vulvar Carcinoma
Interventions
Laser Therapy, Questionnaire Administration, Sham Intervention
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, Minnesota • Fargo, North Dakota + 1 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluate Safety of Tramadol in the Management of Postoperative Pain Following Surgery

NCT03395808
Conditions
Pain Management
Interventions
Tramadol
Drug
Lead sponsor
Avenue Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pasadena, California
Conditions
Pain
Interventions
Routine Care, Distraction
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
4 Years to 9 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Strabismus
Interventions
Tylenol
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
4 Years to 12 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 4 Interventional Results available

Efficacy of IV Acetaminophen for Pain Management

NCT02028715
Conditions
Post-operative Pain
Interventions
Placebo, IV acetaminophen
Drug
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Canton, Ohio
Conditions
Proliferative Diabetic Retinopathy
Interventions
Macugen, Sham
Drug
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Melanoma (Skin)
Interventions
incomplete Freund's adjuvant, melanoma helper peptide vaccine, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide, cyclophosphamide
Biological · Drug
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years to 120 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Houston, Texas • Charlottesville, Virginia
Conditions
Wound, Foot, Diabetic Foot Ulcer (DFU), Venus Leg Ulcer
Interventions
Microlyte®, IP 1: Membrane Wrap - Hydro
Device
Lead sponsor
Capsicure, LLC
Network
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
7
States / cities
San Diego, California • Coral Gables, Florida • Miami, Florida + 3 more
Conditions
Posterior Cervical Surgery, Posterior Cervical Fusion, Posterior Cervical Laminectomy, Posterior Cervical Laminoplasty
Interventions
Clavicle Brace
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Stanford, California
Conditions
Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Childhood Neuroblastoma, Refractory Childhood Osteosarcoma, Refractory Neuroblastoma, Refractory Osteosarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Fludarabine Phosphate, GD2-CAR-expressing Autologous T-lymphocytes, Imaging Procedure, Magnetic Resonance Imaging of the Heart, Multigated Acquisition Scan, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 40 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
6
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 3 more
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Nemtabrutinib, Questionnaire Administration, Venetoclax
Procedure · Drug · Other
Lead sponsor
Jennifer Woyach
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Glenohumeral Arthritis, Total Shoulder Arthroplasty
Interventions
Ropivacaine, liposomal bupivacaine
Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Sarcoma
Interventions
Indocyanine green solution administered at 2.0mg/kg., Stryker SPY-PHI Imaging Device
Drug · Device
Lead sponsor
Kurt Weiss
Other
Eligibility
18 Years to 100 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
Discussion, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Obesity, Prostate Cancer
Interventions
Bariatric Surgery
Other
Lead sponsor
Maimonides Medical Center
Other
Eligibility
20 Years to 60 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Post-Operative Complications in Cardiac Surgery
Interventions
RBT-1, Placebo
Drug
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
29
States / cities
Huntsville, Alabama • San Francisco, California • Stanford, California + 25 more
Conditions
Pain
Interventions
Intervention Arm (STIMFIX)
Other
Lead sponsor
STIMFIX
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Lake Havasu City, Arizona • Los Angeles, California • Clifton, New Jersey
Conditions
Renal Pelvis and Ureter Urothelial Carcinoma
Interventions
Infigratinib, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure
Drug · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Recruiting Phase 1 Interventional Accepts healthy volunteers

PET Detection of CCR2 in Human Atherosclerosis

NCT04537403
Conditions
Carotid Atherosclerosis
Interventions
Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine), Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Completed No phase listed Observational Results available

Utility of Novel BRAF Test for Melanoma

NCT01840527
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults

NCT05205486
Conditions
Infections
Interventions
Cefazolin 3gm for Injection USP and Dextrose Injection USP
Drug
Lead sponsor
B. Braun Medical Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Columbus, Georgia • Oklahoma City, Oklahoma